Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Accenture
Colorcon
Boehringer Ingelheim
Julphar
Queensland Health
Cipla
Dow
Harvard Business School

Generated: January 21, 2019

DrugPatentWatch Database Preview

Capecitabine - Generic Drug Details

« Back to Dashboard

What are the generic sources for capecitabine and what is the scope of capecitabine patent protection?

Capecitabine is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal Pharms, Eugia Pharma, Msn Labs Pvt Ltd, Mylan Pharms Inc, Shilpa Medicare Ltd, Teva Pharms Usa, West-ward Pharms Int, and Hoffmann La Roche, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-eight drug master file entries for capecitabine. Twenty suppliers are listed for this compound.

Pharmacology for capecitabine
Medical Subject Heading (MeSH) Categories for capecitabine

US Patents and Regulatory Information for capecitabine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Pharms Inc CAPECITABINE capecitabine TABLET;ORAL 090943-002 Aug 8, 2014 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Msn Labs Pvt Ltd CAPECITABINE capecitabine TABLET;ORAL 209365-001 Jul 2, 2018 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for capecitabine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-001 Apr 30, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Hoffmann La Roche XELODA capecitabine TABLET;ORAL 020896-002 Apr 30, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Fish and Richardson
Johnson and Johnson
Moodys
Merck
Julphar
US Department of Justice
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.